Related references
Note: Only part of the references are listed.Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Katy L. Cooper et al.
BMC CANCER (2011)
Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma
Hans Wildiers et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
G. von Minckwitz et al.
EUROPEAN JOURNAL OF CANCER (2009)
Myeloid Growth Factors
Jeffrey Crawford et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Hematopoietic growth factors: ESMO Recommendations for the applications
R. Greil et al.
ANNALS OF ONCOLOGY (2008)
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
A. del Giglio et al.
BMC CANCER (2008)
Novel Strategies for Granulocyte Colony-Stimulating Factor Treatment of Severe Prolonged Neutropenia Suggested by Mathematical Modeling
Eliezer Shochat et al.
CLINICAL CANCER RESEARCH (2008)
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study
Ruth Pettengell et al.
SUPPORTIVE CARE IN CANCER (2008)
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
Adi Eldar-Lissai et al.
VALUE IN HEALTH (2008)
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer:: A randomized phase 2 trial
G. Romieu et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
Lionel Pinto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices
Vicki A. Morrison et al.
JOURNAL OF MANAGED CARE PHARMACY (2007)
Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim
Lodovico Balducci et al.
ONCOLOGIST (2007)
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use
Howard Ozer et al.
ONCOLOGIST (2007)
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2006)
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
NM Kuderer et al.
CANCER (2006)
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
D Weycker et al.
ANNALS OF PHARMACOTHERAPY (2006)
Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: A comparison of filgrastim or lenograstim with pegfilgrastim
Walter Schippinger et al.
ONCOLOGY (2006)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma
A Grigg et al.
LEUKEMIA & LYMPHOMA (2003)
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma
JK Doorduijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment:: results of a Nordic Lymphoma Group randomized trial
E Ösby et al.
BLOOD (2003)
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer
FA Holmes et al.
ANNALS OF ONCOLOGY (2002)
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis
GH Lyman et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Share Paper
